Conference Reports for NATAP

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015 Back

Daclatasvir Exposure Does Not Explain Lower Sustained Virologic Response Rates in Cirrhotic Patients With HCV Genotype 3 Following 12 Weeks of Daclatasvir Plus Sofosbuvir Treatment       Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco   Eley T, Raybon J, Wang R, Rana K, Huang S-P, Gandhi Y, Cirincione B, LaCreta F, Garimella T Bristol-Myers Squibb Research and Development, Princeton, NJ